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Summary.-The NCA (nonspecific cross-reacting antigen) was assayed in sera of
patients with chronic myeloid leukaemia (CML). It was elevated to a mean value of
145.6 ng/ml (± 104-4 ng/ml) compared to 37-8 ng/ml (± 14-6 ng/ml) the sera of
normal subjects. Patients with active disease generally had higher serum NCA levels
than those with CML in blast crisis. A correlation of the serum NCA levels with the
cellular contents of this antigen was attempted using different methods. Large
variations of serum NCA levels were observed in different patients having roughly
similar white blood cell (WBC) counts. In general a better correlation was observed
between the serum NCA level and the number of maturing myeloid cells than with
the number ofpolymorphs. The staining ofblood smears with anti-NCA serum by an
immunoperoxidase method suggested an explanation for some cases of CML in blast
crisis with normal serum NCA levels inasmuch as the staining of myeloid cells was
very weak or negative in these cases, indicative of a lack ofNCA synthesis in the cells.
In other cases, cellular NCA was measured by radioimmunoassay in maturing
myeloid cells and polymorphs. The mean values were not significantly different from
the NCA values obtained in normal polymorphs. From the NCA content/106 cells and
the polymorph or maturing myeloid cell counts, we calculated the total NCA cell
content/ml of blood. It was much higher than, though poorly correlated with, the
serum NCA level. Thus factors other than NCA cellular content, mainly the rate of
NCA release from the myeloid cells, might play an important role in the regulation of
its serum level.
THE NONSPECIFIC cross-reacting antigen
(NCA) has been described by different
authors (Mach & Pusztaszeri, 1972;
Newman et al., 1972; von Kleist et al,
1972; Darcy et al., 1973). This antigen
bears common antigenic determinants
with carcinoembryonic antigen (CEA), but
it also has unique determinants so that itis
possible to prepare specificantiseraagainst
it. A quite similar cell and tissue localiza-
tion to that ofCEA has been demonstrated
by immunofluorescence in normal and
gastrointestinal tissues (Burtin et al.,
1973). NCA has also been found in alveolar
macrophages, in normal polymorphs from
peripheral blood (Bordes et al. 1975;
Burtin et al., 1975), and in precursor cells
of normal and pathological myeloid series
(Burtin et al., 1980).
NCA has been assayed in normal and
pathological sera using radioimmunologi-
cal methods (Edgington et al., 1976; von
Kleist et at., 1977a, b). We also demon-
strated (Frenoy & Burtin, 1980) that the
serum NCA level was decreased in acute
myeloid leukaemia (AML) and highly
increased in patients with chronic myeloid
leukaemia (CML).N. FReNOY ET AL.
In the present study, a higher number of
CML patients was studied and we have
confirmed our initial results. However, the
NCA level, although generally high, was
quite variable in CML patients. In order to
find an explanation for this variability, we
investigated clinical and histological para-
meters, such as the stage ofthe disease, the
white blood cell (WBC) and polymorph
counts and the NCA cellular content.
We also obtained some indication ofthe
rate ofNCA release from the cells into the
plasma.
MATERIALS AND METHODS
Serum samples.-Serum samples from 62
healthy subjects (26 males and 36 females)
obtained from the sera bank set up inVillejuif
constituted our control group.
One hundred and forty-three serum
samples from 77 patients with CML (42 males,
35 females), were obtained from the Haemat-
ology Department of the Institut Gustave
Roussy, and the Institut de Cancerologie et
d'Immunogenetique, Villejuif, France, from
the Department ofHaematology, the General
Infirmary at Leeds, England, and from the
Blood Bank ofSt Louis Hospital, Paris.
When subjects were studied several times
during chemotherapy, only the first sample
obtained before chemotherapy was used for
statistical studies.
The stage of the disease at the monrent of
sampling was known for 63 patients, and 9
patients were studied longitudinally.
Preparation of pure NCA and labelling.
NCA was prepared from perchloric extracts of
normal lung and the purity ofthe preparation
was checked as previously described (Burtin
& Chavanel, 1973).
The labelling with 125I was made by the
chloramine T method ofHunter & Greenwood
(1964) and gave a radiolabelled NCA with a
specific activity around 35 tuCi/,tg.
Anti-NCA serum.-Anti-NCA serum was
prepared in rabbits. They were immunized by
2 injections in the foot pads of 70 ,ug of NCA
emulsified in complete Freund's adjuvant
separated by 2 weeks. Animals were exsan-
guinated 2 weeks after the last injection.
Controls for the monospecificity of the
antiserum were conducted as previously
described (Frenoy & Burtin, 1980).
NCA assay.-The NCAradioimmunoassay,
using the double-antibody technique (Egan et
al., 1972) has been described elsewhere
(Frenoy & Burtin, 1980). The anti-NCA
serum was used at a dilution of 1/30,000.
Assays were made twice in duplicate and sera
were reassayed after dilution when NCA
concentrations were >80 ng/ml.
Cell material.-WBC were obtained from
heparinized blood of CML patients (Blood
Bank of St Louis Hospital) after sedimenta-
tion at 37°C. Mononuclear (mainly immature
granulocytic cells in CML patients) and
polymorph fractions were separated using
centrifugation on Ficoll-Isopaque (Phar-
macia, Uppsala, Sweden).
Cells were then counted and one part of
each fraction was used immediately for the
preparation of smears by cytocentrifugation
(Cytospin-Shandon).
Preparation of cell ly8ates.-The other part
of each fraction was frozen and, after
thawing, sonicated to obtain a complete lysis
and NCA liberation. NCA was assayed in the
cellular supernatants obtained by ultra-
centrifugation in a Spinco ultracentrifuge
(30 min at 30,000 rev/min in a 50 TI rotor)
without further extraction.
Immunoperoxidase studies.-For immuno-
peroxidase studies, smears were incubated
with anti-NCA serum, then with peroxidase-
labelled sheep anti-rabbit globulin (Nordic)
and stained with a mixture of amino-ethyl
carbazole and H202 prepared according to
Graham et al. (1965).
Statistical analyses.-The Student-Fisher t
test was used for the comparison of mean
values obtained for the normal and CML
groups (or CML subsets).
RESULTS
(1) Serum NCA concentration in CML
patients and influence of the stage of
the disease
In CML patients, many NCA values
were increased (mean: 145-6 + 104-4
ng/ml; Fig. 1), when compared to the
normal mean value (37-8 + 14-6 ng/ml).
The t test between the 2 means was highly
significant (t= 6-330).
For 61 patients the stage of the disease
was known at the time of the first
sampling. They were classified into 2
groups: Group I, CML patients in active
phase, and Group II, those in blast crisis.
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FIG. 1.-Histogram showing the distribution
of serum NCA levels in the control and
CML group. Results are expressed as percen-
tage of patients vs NCA concentration
(ng/ml).
Results are reported in Table I. The mean
values between the 2 groups were signifi-
cantly different (t= 4 878).
(2) Longitudinal studies
Nine patients were studied over long
periods. They generally gave a rough
parallelism between serum NCA level and
WBC number, and a better one between
NCA and polymorph counts. The correla-
tion with maturing myeloid cells was not
studied in these cases, as the number of
these cells was low due to chemotherapy.
Three cases were closely studied (Figs
2-4). Figs 2 and 4 illustrate a fairly good
correlation between NCA and WBC num-
ber for the same subject. However, the
inter-subject correlation was poor. The
patient illustrated in Fig. 3 showed an
intermittent correlation and cyclical
changes of serum NCA level over a long
period did not apparently correlate with
WBC and polymorph counts.
(3) Study of the correlation between serum
NCA concentration and white blood cell (or
granulocytic cells) number
The relationship of NCA level to WBC,
polymorphs and maturing myeloid cells
was studied in the whole CML group and
in the 2 subsets. Results are summarized
in Table II.
The correlation between NCA level and
total WBC number was better when the
whole CML group was studied. In all the
cases, the correlation was better between
serum NCA level and maturing myeloid
cell number, but no coefficient of correla-
tion exceeded 0-60.
(4) Reactivity of myeloid cells with anti-
NCA serum. Immunoperoxidase study
Sixteen patients were studied, blood
smears were prepared and sera taken at
the same time. These patients had marked
leucocytosis between 40,000 and 515,000
WBC/mm3.
Two patients in blast crisis were taken
among those investigated in the longi-
tudinal studies and were followed for a
long period. Their cells showed a weak or
negative staining and at the same time a
normal serum NCA level was found,
contrasting with the elevated WBC count
(37 ng/ml for 69,000 WBC/mm3 and 47
ng/ml for 40,000 WBC/mm3).
The 14 other patients were in active
phase, with a high proportion ofimmature
cells in their blood. For these patients,
serum and blood were obtained and
mononuclear cells and polymorphs were
TABLE I.-Influence of the stage of the disease on serum NCA concentration
Number Range ng/ml Mean value s.d.
Group I 35 80-458 207-9 103-0
Group II 26 19-5-261 93-1 71-2
Group I: patients in active phase
Group II: patients with a CML in blast crisis.
t-test normal/disease
9-715
5 872
767
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FIG. 2. Longitudinal study: MIL .... a patient with CML in blast crisis. He illustrates the group of
patients who showed a positive correlation between serum NCA concentration an(l white blood
cell (or polymorph) number.
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FIG. 3.-Longitudinal study: WAT .... a patient studied over 2 years. An example of intermittent
correlation between serum NCA level and white cell (or polymorph) count.
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FIG. 4. Longitudinal study: COR . . ., a
patient studied over 2-5 months, with a
very low NCA level despite marked leuco-
cytosis. She had a constant basophilia
and excess of blasts in periplheral blood. N
polymorpbs =neutrophil polymorphs.
separated on Ficoll-Isopaque gradient.
these patients had an increased ser
NCA level (77-458 ng/ml).
The mononuclear fraction (mainly
mature granulocytic cells) often staii
strongly. Myelocytes showed strong p
nuclear staining. In one case, all the c
were strongly positive. In all the ot
cases, heterogeneous staining was se
and immature cells that had apparer
the same morphology were either stron
or weakly positive.
The staining of polymorphs was ger
ally weaker than that of "mononuclear
cells". Individual variation was striking,
with sometimes 15% of negative cells. A
granular pattern was often seen, and
segmented polymorphs were less stained
than band cells.
(5) Determination of NCA cell content by
radioimmunoassay
100 NCA was assayed in the polymorph and
> the mononuclear fractions obtained from
i 17 CML patients.
3 Results are summarized in Table III,
which shows that NCA content/106 cells is
roughly the same in normal and leukaemic
50 granulocytes. From the NCA content per
106 cells, and the number of cells/mm3, we
established a new parameter the NCA
cellular content. The NCA values in all the
10 maturing myeloid cells (1.1-18pg/ml) and
all the polymorphs (2-20 tg/ml) were
much higher than serum NCA level
(66-458 ng/ml).
We examined the correlation between
total cellular content and serum NCA level
in these 17 CML patients. The correlation
was better between serum level and
maturing myeloid cell content (r= 0 448),
All than between serum level and polymorph
um content (r = 04118), but the significance
was weak even in the first comparison
im- (P=O-10). ned
eri-
ells
,her
Len,
Itly
igly
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DISCUSSION
The results described here for CML
patients reinforce our previous con-
clusions. CML patients generally had
higher serum NCA levels than normal
subjects; however mean values were lower
than those published by others (Wahren
et al., 1980).
TABLE II.-Coefficient correlation (r) between serum NCA level and rnyeloid cell number
Whole CML group
Patients with
active disease
Patients with
blast crisis
NCA/total number
ofWVBC
0 *567 (P < 0 001)
0-298 (NS)
NCA/number of
polymorphs
0-327 (P=0-01)
0-068 (NS)
0:354 (NS) 0*507 (P=0 05)
NCA/number of maturing
myeloid cellsa
0-586 (P<0-001)
0-413 (P= 0.02)
0594 (P<001)
a Maturing myeloid cells: promyelocytes +myelocytes+metamyelocytes.
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TABLE III.-Determination of NCA in cellsfrom peripheral blood
Normal subjects
(polymorphs)
CML patients
(polymorphs)
CML patients
(mononuclear
fraction)
Number Range (ng/106 cells)
11 29-99
17 27 5-105
17 16-143
Mean value
(ng/ml)
62*07 21 39
67 54 22 81
66 42 34 36
As it is easy to estimate the tumour
mass according to the number ofWBC per
blood mm3, CML might be one of the best
models to study the parameters regulating
the serum level of an antigen produced by
tumour cells. This is the reason why we
attempted to investigate the relationship
between serum NCA concentration and
WBC (or polymorphs) and, for some
patients, to correlate serum NCA level
with the NCA cell content of the
granulocytic cells.
The relationship between serum NCA
level and WBC count (polymorphs or
maturing myeloid cells) was not generally
strong in the whole CML population or
in the two subsets, and no coefficient of
correlation exceeded 0-6. However, the
correlation was improved between serum
NCA level and maturing myeloid cells
counts-cells which appeared the more
strongly stained in the immunoperoxidase
studies. These results are rather different
from those published by Wahren et al.
(1982), who found a good correlation
between serum NCA level and WBC
number for the whole CML group.
Our data were the same from longi-
tudinal studies. We have shown that the
intra-subject correlation between serum
NCA level and WBC (or polymorphs)
count was better than the inter-subject
correlation, since we found almost identi-
cal serum NCA levels in CML patients with
very different WBC or polymorph counts.
Patients studied during chemotherapy
often revealed a parallelism between
serum NCA level and WBC number;
serum NCA level appears to reflect the
response to treatment.
The immunocytological study of some
individual patients in blast crisis permit-
ted the conclusion that normal or low
serum NCA level, despite a high WBC
count, correlated with weak cell staining.
This was especially true for patients in
blast crisis: the same observation was
made by Heuman et al. (1979). The results
may be explained by the low synthesis of
NCA in the immature leukaemic cells
appearing in the blood.
Furthermore, we failed to demonstrate a
correlation between serum NCA level and
NCA content of granulocytic cells deter-
mined by radioimmunoassay in 17
untreated patients in active phase.
It is worthwhile stressing that the mean
value of cellular NCA was the same for
normal and CML granulocytic cells. This
result is in accordance with those of
Wahren et al. (1980). If we consider now
the cell NCA content/ml of blood, values
were much greater than the serum NCA
levels. This means that only a small
percentage of cellular NCA reaches the
plasma. The correlation between total cell
content and serum level of NCA is poor,
this has to be seen in the light of the
large variation of serum NCA concentra-
tion in CML patients having roughly
similar WBC counts.
If these variations can at best be only
partially explained by the NCA concen-
trations in myeloid cells, then other
hypotheses have to be considered.
The first explanation is the possible
contribution of other cells which are
known to contain NCA such as alveolar
macrophages (Burtin et al., 1975),
monocytes (Burtin & Fondaneche, 1981),
s.d.
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or epithelial cells of the gastrointestinal
mucosa (Burtin et al., 1973). However, it
is likely that in CML patients the main
source of NCA is the granulocytic cells.
Another possible explanation lies in the
rate ofNCA release from cells and the rate
ofNCA catabolism. Here we have recourse
to experience with CEA; for example the
very high levels of serum CEA found in
medullary carcinomas ofthe thyroid could
be explained by the release of CEA from
the basal pole of cancerous cells into the
connective tissue, then into the peripheral
blood (Burtin et al., 1979). In contrast,
breast tumours generally contain intra-
cytoplasmic CEA (von Kleist, 1980),
which fails to enter the blood, and
serum CEA is normal or only weakly
elevated. Thus high tissue concentrations
of the same antigen may lead to very
different serum levels, due to parameters
such as the release rate. In common with
NCA, the cellular amount ofthis antigen is
several 100-fold higher than its serum
level. Thus it is easy to understand how
a small variation in the rate of NCA
release may greatly influence the serum
level ofthis antigen.
We have studied NCA release from the
granulocytic cells of normal subjects and
CML patients under non-physiological
conditions in vitro. These appear to
demonstrate that NCA release is slow in
both categories, and extremely variable
from one subject to another.
If this variability exists also in vivo, it
could explain, at least in part, the inter-
subject variation of serum NCA levels
reported herein.
We are grateful to Professor E. H. Cooper (Unit
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